managing-fertility-evaluations

name	managing-fertility-evaluations
language	en
description	Structures infertility workup with ovarian reserve testing, semen analysis, and treatment algorithms. Use when evaluating infertility, ordering fertility workup, or managing reproductive planning.
tags	["management","obstetrics-and-gynecology","treatment"]
metadata	{"author":"casemark","practice_areas":["Obstetrics","Gynecology","Maternal-Fetal Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Fertility Evaluations

Structures infertility workup with ovarian reserve testing, semen analysis, tubal assessment, and stepped treatment algorithms per ASRM and ACOG Practice Bulletin No. 217.

Why This Skill Exists

Infertility — defined as failure to conceive after 12 months of unprotected intercourse (or 6 months if female partner is ≥ 35) — affects approximately 12–15% of couples. The American Society for Reproductive Medicine (ASRM) recommends a systematic, simultaneous evaluation of both partners, as male factor contributes to approximately 40–50% of infertility cases (sole male factor ~20%, combined male + female ~20–30%). Delays in evaluation lead to age-related decline in ovarian reserve, diminishing treatment success.

ACOG Practice Bulletin No. 217 (Infertility Workup for the Women's Health Specialist) outlines the standard evaluation components. This skill ensures a complete, concurrent evaluation of ovulatory function, tubal patency, uterine anatomy, ovarian reserve, and male factor — then maps findings to the appropriate treatment tier.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Duration of infertility — months of unprotected intercourse? Primary (never conceived) or secondary (prior pregnancy)? (Default: from history)
2. Female partner age — critical for prognosis and urgency of evaluation. (Default: from demographics)
3. Coital frequency and timing — intercourse frequency and relationship to ovulation? Use of ovulation prediction kits? (Default: from history)
4. Menstrual history — cycle length, regularity, signs of ovulatory dysfunction (oligomenorrhea, amenorrhea)? (Default: from menstrual calendar)
5. Obstetric and gynecologic history — prior pregnancies (with any partner), ectopic, PID, endometriosis, uterine surgery? (Default: from history)
6. Male partner history — prior paternity, testicular surgery, varicocele, medications, toxin exposure, ejaculatory dysfunction? (Default: from male partner history)
7. Medical comorbidities — thyroid disease, PCOS, hyperprolactinemia, DM, eating disorders, excessive exercise? (Default: from problem list)
8. Social factors — tobacco, alcohol, marijuana, occupation, environmental exposures? (Default: from social history)

Documents to Request

• Prior fertility evaluation results (both partners)
• Semen analysis report(s)
• HSG or SHG reports
• Ovarian reserve testing (AMH, day-3 FSH/estradiol, antral follicle count)
• Thyroid function tests
• Prolactin level
• Prior operative reports (laparoscopy, hysteroscopy, tubal surgery)
• Genetic testing results (karyotype, FMR1, carrier screening)
• Partner medical records if available

---

Step 1: Ovulatory Assessment

Ovulatory dysfunction accounts for approximately 25–30% of female infertility.

Assessment Method	Timing	Interpretation
Menstrual history	Ongoing	Regular 24–35 day cycles strongly suggest ovulation
Basal body temperature (BBT)	Daily	Biphasic pattern (0.2–0.5°C rise) confirms ovulation retrospectively
Urine LH surge (OPK)	Mid-cycle	Positive predicts ovulation in ~24–36 hours
Mid-luteal progesterone	Day 21 (or 7 days post-expected ovulation)	> 3 ng/mL confirms ovulation
Endometrial biopsy	Luteal phase	No longer routinely recommended for dating; useful if endometrial pathology suspected

Ovulatory Dysfunction Workup

Condition	Testing	Findings
PCOS	Rotterdam criteria: 2 of 3 — oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on US	Elevated free testosterone, DHEA-S; LH:FSH ratio > 2:1 (supportive but not required)
Hypothalamic amenorrhea	FSH, LH, estradiol	Low/normal FSH, low LH, low estradiol
Hyperprolactinemia	Prolactin	> 25 ng/mL — repeat; if persistent, consider MRI pituitary
Thyroid dysfunction	TSH	Abnormal TSH → treat before fertility intervention
Premature ovarian insufficiency	FSH, AMH, estradiol	FSH > 40 IU/L (× 2 samples), low AMH, low estradiol

---

Step 2: Ovarian Reserve Assessment

Ovarian reserve predicts the quantity (not quality) of remaining oocytes and guides treatment intensity.

Test	Timing	Normal Values	Interpretation
AMH (anti-Müllerian hormone)	Any cycle day	1.0–3.5 ng/mL	< 1.0 = diminished reserve; > 3.5 = possible PCOS
Day 3 FSH	Cycle day 2–4	< 10 IU/L	> 10 = diminished reserve; > 15 = poor prognosis
Day 3 estradiol	Cycle day 2–4	< 80 pg/mL	Elevated E2 with normal FSH may mask diminished reserve
Antral follicle count (AFC)	Cycle day 2–5 (TVUS)	10–20 total	< 5–7 = diminished reserve; > 20 = high responder / PCOS risk

Combine AMH + AFC for the most accurate reserve assessment. Document results with age-adjusted interpretation.

---

Step 3: Tubal and Uterine Evaluation

Test	What It Assesses	Findings
Hysterosalpingogram (HSG)	Tubal patency, uterine cavity contour	Bilateral spill = patent tubes; filling defects = polyps/fibroids/synechiae; proximal vs. distal tubal occlusion
Saline infusion sonohysterogram (SIS)	Uterine cavity detail	Polyps, submucosal fibroids, Asherman syndrome
Hysteroscopy	Direct cavity visualization	Gold standard for intracavitary pathology — see and treat
Laparoscopy with chromopertubation	Tubal patency + peritoneal disease	Reserve for suspected endometriosis, PID, or equivocal HSG

Uterine anomalies affecting fertility:

• Septate uterus — most common anomaly associated with pregnancy loss; hysteroscopic septum resection improves outcomes
• Unicornuate uterus — reduced cavity volume, associated with preterm delivery
• Asherman syndrome — intrauterine adhesions from prior instrumentation; hysteroscopic lysis

---

Step 4: Male Factor Evaluation

Semen analysis is the cornerstone of male factor assessment. Per WHO 6th edition (2021) reference values:

Parameter	Lower Reference Limit (5th percentile)
Volume	≥ 1.4 mL
Sperm concentration	≥ 16 million/mL
Total sperm count	≥ 39 million per ejaculate
Progressive motility	≥ 30%
Total motility	≥ 42%
Normal morphology (strict Kruger)	≥ 4%

• Abnormal semen analysis → repeat in 4–12 weeks (values fluctuate)
• Persistently abnormal → urology referral for evaluation (hormonal — FSH, testosterone, prolactin; physical exam — varicocele; genetic — Y-microdeletion, karyotype if severe oligospermia < 5 million/mL)
• Azoospermia → obstructive vs. non-obstructive classification; refer to reproductive urologist

---

Step 5: Treatment Algorithm

Diagnosis	First-Line Treatment	Second-Line	Third-Line
Ovulatory dysfunction (PCOS)	Letrozole 2.5–7.5 mg CD 3–7 (superior to clomiphene per NICHD trial)	Clomiphene 50–150 mg CD 5–9; gonadotropins	IVF
Unexplained infertility	Timed intercourse × 3–6 cycles → letrozole/clomiphene + IUI × 3	Gonadotropins + IUI (up to 3 cycles)	IVF
Tubal factor (bilateral occlusion)	IVF (bypass tubal disease)	Tubal surgery (selected cases with mild distal disease)	—
Male factor (mild-moderate)	IUI with sperm wash (requires ≥ 5–10 million TMSC)	IVF	IVF-ICSI
Male factor (severe / azoospermia)	IVF-ICSI with TESE/micro-TESE if needed	Donor sperm	—
Diminished ovarian reserve	Aggressive stimulation → IVF	Donor oocytes	—
Endometriosis	Surgical excision + spontaneous attempt × 6 months	IUI with controlled stimulation	IVF

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Are both partners evaluated — ovulatory function, tubal patency, ovarian reserve, and semen analysis all addressed?
2. Is ovarian reserve documented with age-adjusted interpretation?
3. Is the treatment recommendation matched to the specific diagnosis?
4. Are time-sensitive factors addressed — female age, duration of infertility, and declining reserve?
5. Is the referral to reproductive endocrinology documented when indicated (e.g., bilateral tubal disease, DOR, severe male factor)?

---

Quality Audit

• Duration and type (primary vs. secondary) of infertility documented
• Female partner age documented with prognostic implications noted
• Ovulatory assessment completed (menstrual history + mid-luteal progesterone or OPK)
• Ovarian reserve testing documented (AMH + AFC or day-3 FSH/E2)
• TSH and prolactin documented
• HSG or SIS performed and results documented
• Semen analysis performed with WHO 6th edition reference values applied
• Abnormal semen analysis repeated and/or urology referral documented
• Uterine cavity evaluation completed
• PCOS evaluation documented using Rotterdam criteria (if oligoovulation present)
• Treatment plan documented with tier-appropriate recommendation
• Genetic screening offered (carrier screening per ACOG, karyotype if indicated)
• Pre-conception counseling documented (folate, weight optimization, substance cessation)
• Timeline for treatment escalation documented

---

Guidelines

1. Evaluate both partners simultaneously — do not complete the full female workup before ordering a semen analysis; male factor is present in 40–50% of cases.
2. Age drives urgency — women ≥ 35 should be referred after 6 months; women ≥ 40 warrant immediate evaluation.
3. Letrozole is first-line for PCOS ovulation induction — the NICHD PPCOS II trial demonstrated higher live birth rates with letrozole vs. clomiphene.
4. Do not skip ovarian reserve testing — even in young patients, diminished reserve changes the treatment approach and timeline.
5. Document the AFC method — report bilateral antral follicle count with probe frequency and technique for reproducibility.
6. Recognize when to refer — bilateral tubal occlusion, severe male factor, diminished ovarian reserve, and age ≥ 38 with > 6 months of failed first-line treatment should be referred to a reproductive endocrinologist.
7. Counsel on realistic expectations — per-cycle success rates for IUI are 10–20%, and IVF success rates are age-dependent (age < 35: ~50% live birth per transfer; age 40–42: ~15%).
8. Address lifestyle factors — BMI optimization (ideal 19–25), smoking cessation, alcohol limitation, and caffeine < 200 mg/day all impact fertility.